https://doi.org/10.1140/epjp/s13360-023-04564-3
Regular Article
Cyclotron-based production of innovative medical radionuclides at the INFN-LNL: state of the art and perspective
1
National Institute of Nuclear Physics, Legnaro National Laboratories (INFN-LNL), Viale dell’Università 2, 35020, Legnaro, Italy
2
Department of Physical Sciences, Earth and Environment, University of Siena, Siena, Italy
3
Department of Physics and Astronomy, University of Padova, Via Marzolo 8, 35131, Padova, Italy
4
Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy
5
INFN Ferrara, Via Saragat 1, 44122, Ferrara, Italy
6
INFN Pisa, Edificio C - Polo Fibonacci Largo B. Pontecorvo, 3, 56127, Pisa, Italy
7
Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy
8
Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128, Padova, Italy
Received:
2
August
2023
Accepted:
2
October
2023
Published online:
10
December
2023
The production of medical radionuclides is one of the research activities carried out in the framework of the SPES (Selective Production of Exotic Species) project under the completion stage at the Legnaro National Laboratories of the National Institute for Nuclear Physics (INFN-LNL). The heart of SPES is the 70-MeV proton cyclotron having a dual-beam extraction, installed and commissioned in a new building equipped with ancillary laboratories currently under construction. The SPES main goal is the realization of an advanced ISOL (Isotope Separation On-Line) facility to produce re-accelerated exotic ion beams for fundamental nuclear physics studies. The cyclotron double-beam extraction system allows to simultaneously carry out applied research, such as radionuclides production for medicine (SPES-
). This paper summarizes the results obtained with the interdisciplinary projects LARAMED (LAboratory of RAdionuclides for MEDicine) and ISOLPHARM (ISOL technique for radioPHARMaceuticals). The first one, based upon the direct activation method, is focused on the production of the radionuclides under the spotlight of the international community (e.g., 
Tc, 
Cu, 
Mn, 
Sc and Tb isotopes), from the nuclear cross-section measurements up to the preclinical studies. The other one exploits the ISOL technique for the development and production of radioisotopes with high-specific activity, such as 
Ag, going beyond the state of the art in the field. The most recent SPES- research activities and future perspective are here described, characterized by a consolidated network of collaborations with national and international institutions.
© The Author(s) 2023
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
